Lymphocytes Subpopulation in Cancer Patients

NCT ID: NCT02516371

Last Updated: 2015-08-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-08-31

Study Completion Date

2018-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to exam the subpopulation of lymphocytes and evaluate the clinico-pathologic correlations.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The host's inflammatory response in the tumor microenvironment could effect cancer progression and prognosis. As components of systemic inflammatory response, lymphocytes, neutrophils, and platelets are being recognised to have an important role in carcinogenesis and tumor progression. To date, a number of peripheral blood-derived inflammation-based scores such as the neutrophil-lymphocyte ratio (NLR), platelet- lymphocyte ratio (PLR) and so on have been proposed as prognostic markers in numerous types of cancers. But, very little is known of their impact in subpopulation of lymphocytes. The investigators try to evaluate the activity of lymphocytes in peripheral blood and find out the relationship among clinical prognosis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

lymphocytes

To evaluate the subpopulation of lymphocytes in cancer patients

Group Type OTHER

lymphocyte

Intervention Type OTHER

To evaluate the subpopulation of lymphocytes in cancer patients

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

lymphocyte

To evaluate the subpopulation of lymphocytes in cancer patients

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

subpopulation of lymphocytes in cancer patients

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. cancer patients of Uijeongbu St. Mary's Hospital
2. never treated with chemotherapy
3. Age between 20\~80 years-

Exclusion Criteria

1. treated with chemotherapy before
2. No informed consent form
Minimum Eligible Age

20 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

DERSHENG SUN

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

DERSHENG SUN

Clinical assistant professor

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Yoon Ho Ko, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Uijeongbu St. Mary's Hospital, The Catholic University of Korea

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Uijeongbu St. Mary's hospital, the Catholic university of Korea

Uijeongbu-si, Gyounggido, South Korea

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Yoon Ho Ko, MD, PhD

Role: CONTACT

82-31-820-3985

Der Sheng Sun, MD, PhD

Role: CONTACT

82-31-820-3584

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

SUN DER SHENG, MD, PhD

Role: primary

+82318203584

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

UC15OISI0093

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Immuno-Oncology Database and Bioregistry
NCT04656873 ACTIVE_NOT_RECRUITING
Tumor-specific T Cells in Lung Cancer
NCT02515760 ACTIVE_NOT_RECRUITING NA